Trisodium phosphate dodecahydrate
Names
[ CAS No. ]:
10101-89-0
[ Name ]:
Trisodium phosphate dodecahydrate
[Synonym ]:
trisodium,phosphate,dodecahydrate
Sodium phosphate,tribasic dodecahydrate
MFCD00149198
Sodium phosphate hydrate (3:1:12)
Phosphoric acid, trisodium salt, dodecahydrate
Trisodium phosphate dodecahydrate
Sodium phosphate tribasic dodecahydrate
EINECS 231-509-8
Phosphoric acid trisodium salt dodecahydrate
Sodium phosphate dodecahydrate
Biological Activity
[Description]:
[Related Catalog]:
[References]
Chemical & Physical Properties
[ Density]:
1.62
[ Boiling Point ]:
158ºC at 760 mmHg
[ Melting Point ]:
75 °C
[ Molecular Formula ]:
H24Na36O16P
[ Molecular Weight ]:
380.18
[ Exact Mass ]:
380.049500
[ PSA ]:
206.82000
[ Index of Refraction ]:
1.4458
[ Storage condition ]:
Store at RT.
[ Stability ]:
Stable. Incompatible with strong acids. Keep dry.
[ Water Solubility ]:
258 g/L (20 ºC)
MSDS
Toxicological Information
CHEMICAL IDENTIFICATION
- RTECS NUMBER :
- TC9575000
- CHEMICAL NAME :
- Phosphoric acid, trisodium salt, dodecahydrate
- CAS REGISTRY NUMBER :
- 10101-89-0
- LAST UPDATED :
- 199504
- DATA ITEMS CITED :
- 4
- MOLECULAR FORMULA :
- O4-P.3Na.12H2-O
- MOLECULAR WEIGHT :
- 380.18
- WISWESSER LINE NOTATION :
- NA3 P-O4 &QH 12
HEALTH HAZARD DATA
ACUTE TOXICITY DATA
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 7400 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- AIHAAP American Industrial Hygiene Association Journal. (AIHA, 475 Wolf Ledges Pkwy., Akron, OH 44311) V.19- 1958- Volume(issue)/page/year: 30,470,1969
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 430 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- COREAF Comptes Rendus Hebdomadaires des Seances, Academie des Sciences. (Paris, France) V.1-261, 1835-1965. For publisher information, see CRASEV. Volume(issue)/page/year: 257,791,1963 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOHS - National Occupational Hazard Survey (1974) NOHS Hazard Code - T1585 No. of Facilities: 154 (estimated) No. of Industries: 2 No. of Occupations: 2 No. of Employees: 308 (estimated) NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - T1585 No. of Facilities: 3662 (estimated) No. of Industries: 36 No. of Occupations: 31 No. of Employees: 31308 (estimated) No. of Female Employees: 6999 (estimated)
Safety Information
[ Symbol ]:
GHS07
[ Signal Word ]:
Warning
[ Hazard Statements ]:
H315-H319-H335
[ Precautionary Statements ]:
P305 + P351 + P338
[ Personal Protective Equipment ]:
Eyeshields;Faceshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges
[ Hazard Codes ]:
C:Corrosive
[ Risk Phrases ]:
R35
[ Safety Phrases ]:
S26-S36/37/39-S45
[ RIDADR ]:
UN 3262 8/PG 3
[ WGK Germany ]:
1
[ RTECS ]:
TC9575000
[ Packaging Group ]:
III
[ Hazard Class ]:
8
[ HS Code ]:
2835291000
Customs
[ HS Code ]: 2835291000
Articles
PLoS Negl. Trop. Dis. 9 , e0003949, (2015)
Opisthorchis viverrini is distinct among helminth infections as it drives a chronic inflammatory response in the intrahepatic bile duct that progresses from advanced periductal fibrosis (APF) to chola...
Reductive dechlorination of carbon tetrachloride using buffered alkaline ascorbic acid.Chemosphere 136 , 27-31, (2015)
Alkaline ascorbic acid (AA) was recently discovered as a novel in-situ chemical reduction (ISCR) reagent for remediating chlorinated solvents in the subsurface. For this ISCR process, the maintenance ...
Metabolic imaging of pancreatic ductal adenocarcinoma detects altered choline metabolism.Clin. Cancer Res. 21(2) , 386-95, (2015)
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive and lethal disease that develops relatively symptom-free and is therefore advanced at the time of diagnosis. The absence of early symptoms and ...